SeaStar Medical Reports Q3 2026: Revenue Up 247% to $0.6 Million, Net Loss Widens to -$4.5 Million
QUELIMMUNE adoption accelerates while R&D spending climbs on NEUTRALIZE-AKI trial progress Related Stocks: ICU ,
QUELIMMUNE adoption accelerates while R&D spending climbs on NEUTRALIZE-AKI trial progress Related Stocks: ICU ,